The Nordic Twin Study on Cancer - NorTwinCan by Nordic Twin Study Canc NorTwinCan et al.
Article
The Nordic Twin Study on Cancer — NorTwinCan
Jennifer R. Harris1, Jacob Hjelmborg2, Hans-Olov Adami3,4, Kamila Czene3, Lorelei Mucci5, Jaakko Kaprio6 and Nordic
Twin Study of Cancer (NorTwinCan) Collaboration
1Division of Health Data and Digitalisation, Norwegian Institute of Public Health, Oslo, Norway, 2Danish Twin Registry, Institute of Public Health, University of
Southern Denmark, Odense, Denmark, 3Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, 4Clinical Effectiveness
Research Group, Institute of Health, University of Oslo, Oslo, Norway, 5Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
and 6Department of Public Health and Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
Abstract
Nordic twin studies have played a critical role in understanding cancer etiology and elucidating the nature of familial effects on site-specific
cancers. The NorTwinCan consortium is a collaborative effort that capitalizes on unique research advantages made possible through the
Nordic system of registries. It was constructed by linking the population-based twin registries of Denmark, Finland, Norway and Sweden
to their country-specific national cancer and cause-of-death registries. These linkages enable the twins to be followedmany decades for cancer
incidence andmortality. To date, twomajor linkages have been conducted: NorTwinCan I in 2011–2012 and NorTwinCan II in 2018. Overall,
there are 315,413 eligible twins, 57,236 incident cancer cases and 58 years of follow-up, on average. In the initial phases of our work,
NorTwinCan established the world’s most comprehensive twin database for studying cancer, developed novel analytical approaches tailored
to address specific research considerations within the context of the Nordic data and leveraged these models and data in research publications
that provide the most accurate estimates of heritability and familial risk of cancers reported in the literature to date. Our findings indicate an
excess familial risk for nearly all cancers and demonstrate that the incidence of cancer among twins mirrors the rate in the general population.
They also revealed that twin concordance for cancermost oftenmanifests across, rather thanwithin, cancer sites, andwe are currently focusing
on the analysis of these cross-cancer associations.
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For more than half a century, data from the Nordic twin cohorts
have helped elucidate the importance and nature of familial effects
on the development of cancers (Ahlbom et al., 1997; Harvald &
Hauge, 1963; Lichtenstein et al., 2000; Mucci et al., 2016).
Earlier twin studies confirmed reports of familial clustering for
cancers at common sites (Easton, 1994; Lynch et al., 1995) and fur-
ther extended these findings to conclude that familial effects played
a major role for cancers at all sites and for total cancer (Ahlbom
et al., 1997). The prevailing interpretation, based on data from sin-
gle countries, was that these familial influences primarily reflected
the effects of shared environments (Ahlbom et al., 1997; Harvald &
Hauge, 1963). However, to fully exploit the twin design for probing
the nature of familial effects on cancer requires larger samples
of concordant and discordant pairs than are typically available
through single-country studies.
Findings from a landmark study (Lichtenstein et al., 2000) that
leveraged twin and cancer data from the Swedish, Danish and
Finnish registries and included nearly 45,000 twin pairs also
emphasized the primacy of environmental influences for most
types of cancers. However, that study also noted an increased risk
of cancer to twins whose co-twin had developed certain types of
cancers, including stomach, colorectal, lung, breast and prostate
cancer. Furthermore, heritability estimates were moderately large
for prostate, colorectal and breast cancer. Although the popula-
tion-based sample of twins studied in this multicountry initiative
was quite large and the confidence intervals for the heritability esti-
mates were wide, heritability could not be calculated for the less
common cancers, and statistical power to parse familial sources
of cancer clustering into genetic and shared environmental
influences was limited.
Moreover, a common methodological limitation of most pre-
vious twin cancer studies was that analyses did not take into
account the considerable amount of censoring that can occur at
both the beginning and end of follow-up, as well as competing
causes of death—which is particularly important in epidemiologi-
cal studies of cancer, given the relatively late-life incidence of most
forms of cancer. Ignoring such censoring can severely bias the inci-
dence and risk concordance estimates and can affect estimates of
heritability.
To overcome these shortcomings and enable more in-depth
analyses of the genetic and environmental influences on cancer,
we established the NorTwinCan (Nordic Twin Study of Cancer)
consortium (http://nortwincan.org). This collaborative effort
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builds heavily on the previous Nordic twin registry collaboration
(Lichtenstein et al., 2000) and unites cancer epidemiologists, bio-
statisticians and twin researchers from multiple institutes span-
ning the Nordic countries and the United States. NorTwinCan
capitalizes on unique research advantages made possible through
the Nordic system of registries in Denmark, Finland, Norway
and Sweden. In its initial phase, NorTwinCan established the
world’s most comprehensive twin database for studying cancer.
It expanded the previous large Nordic twin study base
(Lichtenstein et al., 2000) with the addition of the Norwegian twin
cohort, and 10 more years of follow-up for cancer incidence, pro-
viding a median follow-up of 32 years. We refer to these data as
NorTwinCan I; subsequent updates to the data are described later
as NorTwinCan II.
An important new feature of NorTwinCan is that we developed
novel analytical models tailored to address specific methodological
considerations within the context of the Nordic data. This included
accounting for competing risks of death, for left-censoring that
arises due to variable initiation of the time of cancer registration,
and right-censoring whereby different potential outcomes could
explain an individual’s status at follow-up (Scheike et al., 2014,
2015). These approaches were applied in analyses that provide
the most accurate estimates of heritability (Hjelmborg,
Korhonen et al., 2017; Hjelmborg et al., 2014; Moller et al.,
2016; Mucci et al., 2016) and familial risk (Mucci et al., 2016) of
cancers reported in the literature to date.
One of the most compelling findings to emerge from our ini-
tial analysis of the NorTwinCan data revealed that twin concord-
ance for cancer most often manifests across, rather than within,
cancer types (Mucci et al., 2016); namely, if one twin has cancer,
the co-twin is at an increased risk to develop cancer, but this
cancer usually occurs at a different site. In NorTwinCan, cancer
was diagnosed in both twins among 1383 monozygotic (MZ)
pairs and among 1933 dizygotic (DZ) pairs. However, only
38% of the MZ pairs and 26% of the DZ pairs were diagnosed with
the same type of cancer. These findings prompted a new
NorTwinCan substudy to investigate familial risk of cross-cancer
associations.
To help maintain NorTwinCan as a world-class research re-
source, and with novel plans to analyze the cross-cancer associa-
tions, we expanded the NorTwinCan database through a
renewed round of registry linkages that were completed from
2016 through 2018. The national twin registries were linked to
the national cancer registries in Denmark, Finland, Norway and
Sweden. These updates provided additional years of follow-up
across the four countries and more than doubled the number of
incident cancers to more than 57,000. A preliminary description
of the updated data is provided in Table 1. Analyses of the
cross-cancer associations are now underway using the updated
data, which will greatly enhance our statistical power.
NorTwinCan Cohorts
The NorTwinCan study was constructed by linking the population-
based twin registries of Denmark, Finland, Norway and Sweden to
their country-specific national cancer and cause-of-death registries.
These Nordic twin registries are continually evolving as new studies,
data collections and data updates are conducted. A recent
NorTwinCan publication (Skytthe et al., 2019) describes informa-
tion about the participating twin registries including the dates of
establishment, birth cohorts and sample sizes. Further, more
detailed information is also provided in this special issue of the jour-
nal for the country-specific registries.
Each country participating in NorTwinCan maintains a system
of national registers through which information about vital status,
date and cause of death, migration and systematic registration of
cancer diagnosis and other cancer-related variables are registered.
Record linkage between the information in the twin registries with
data in the cancer and other population registries can be performed
because every citizen in the Nordic countries is assigned an indi-
vidually unique national registration number. Conducting such
linkage for research purposes requires full compliance with the
General Data Protection Regulation of the European Union
(EU-GDPR, 2016) and typically involves obtaining permissions
from the relevant entities including the national data protection
authorities, regional ethics committees and the boards of the twin
registers.
The first linkages for NorTwinCan I were conducted in 2011–
2012. At that time, the cancer registration was complete through
2008 for Norway, 2009 for Denmark and Sweden and 2010 for
Finland (Mucci et al., 2016). The NorTwinCan I database included
information on more than 350,000 twin individuals, including
80,309 MZ twins, 123,382 same-sex DZ (SSDZ) twins and
96,499 opposite-sex DZ (OSDZ) twins. Through linkage to the
cancer and cause-of-death registries in the participating countries
the median follow-up time for cancer incidence and mortality was
28.3 years from 1943 to 2010. There were 62,522 individuals who
died of any cause, 3804 individuals who emigrated and were lost to
follow-up, and zygosity information was missing for 5375 individ-
uals. Altogether, we identified 27,156 incident cancers among
23,980 individuals.
The NorTwinCan II linkage update was completed in 2018 and
included all cancer registrations through 2016 for Denmark,
Finland and Norway, and Sweden. Table 1 shows the number of
additional years of follow-up this encompassed for each country.
NorTwinCan II includes 315,418 eligible twins and 57,236 incident
cancer cases, and 58 years of follow-up, on average, calculated as
the weighted number of contributing cases from each cohort.
The core data obtained from the cancer registries consists of
information about the occurrence of cancer covering 40 different
and most common cancer sites based on the NordCan
Table 1. Overview of follow-up dates for NorTwinCan I and II and current number of incident cases
Denmark Finland Norway Sweden
Follow-up
Cancer registration start date January 1943 February 1974 January 1964 April 1961
End of follow-up NorTwinCan I December 2009 December 2010 December 2008 December 2009
End of follow-up NorTwinCan II December 2016 December 2016 December 2016 December 2016
N incident cases NorTwinCan II 16,172 9061 5638 26,365
Note: NorTwinCan II is an updated database of NorTwinCan I, and therefore, includes all number of incident cases as of December 2016.
818 Jennifer R. Harris et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/thg.2019.71
Downloaded from https://www.cambridge.org/core. Helsinki University Library, on 19 Mar 2020 at 11:29:19, subject to the Cambridge Core terms of use, available at
classification of sites (Engholm et al., 2010). All diagnoses are based
on the International Classification of Diseases, 10th Revision (ICD-
10) coding from the population-based registries, with the NordCan
grouping of ICD codes enabling comparability across countries
(http://www-dep.iarc.fr/nordcan.htm). In addition, the participat-
ing twin registries have exposure measures, including information
on body composition at multiple ages for each individual and life-
style factors known to affect cancer risk, such as tobacco smoking
status and alcohol consumption, are also available in at least half of
the cohort.
Development of Statistical Models
The first important consideration in modeling twin data to quantify
genetic and environmental contributions to cancer occurrence is to
decide on how to treat the timing of events within the pair. The ini-
tiation of population-wide registration of cancer diagnoses and the
collection of retrospective and prospective data on twins in each pop-
ulation provides critical information regarding the timing of events,
diagnosis and vital status at follow-up for each member of the pair.
The information available from the beginning of cancer registration
is the date of diagnosis and status of the twins, and whether the
co-twin of a diagnosed twin is alive at follow-up, dead or also diag-
nosed with a certain cancer, and the age at the co-twins’ diagnosis.
The classic approach to parsing sources of variation into genetic
and environmental effects relies on methods that compare within
pair dependence between MZ and DZ pairs. This was described
over a century ago in a landmark paper (Fisher, 1918) and applies
naturally to (continuous) traits observed completely in all individ-
uals. Historically, as shown in the first twin study of cancer out-
comes with Nordic twin data from the Danish cohort (Harvald
& Hauge, 1963), initial modeling attempts of the observed data
relied on dichotomizing the time to event as either having a specific
cancer diagnosis or not and comparing rates of concordance by
zygosity. In that paper the authors noted that results may be
influenced by unobserved cancer occurrences due to censoring at
follow-up (Harvald & Hauge, 1963).
AlthoughHarvald andHauge (1963) are inconclusive regarding
genetic and environmental influences for the risk to develop cancer
at various anatomical sites, the notion that the risk of cancer in a
twin given that their co-twin has had the cancer (before follow-up
or death) highlights an important measure of dependence that has
been applied in subsequent studies in the field. In the later Nordic
follow-up (Lichtenstein et al., 2000) in which some 90,000 Nordic
twins were studied, the sources of variation in liability to develop
cancer was studied through the (bivariate) liability-threshold
model in which prevalence (again at follow-up) determines the
threshold on the latent trait of liability to cancer. This approach
provides within-pair correlations, termed tetrachoric correlations,
having the properties that within-pair dependence is independent
of the prevalence of the cancer. The tetrachoric correlations may be
compared by zygosity and further modeled directly by the poly-
genic biometric model from quantitative genetics, often referred
to as the ‘ADCE-model’. This classic biometric modeling decom-
poses the variance of the trait, here liability to develop cancer, into
independent additive (A) and dominant (D) genetic contributions
to the variance, and environmental contributions of shared effects,
C, and unique individual effects including measurement error, E.
Thismodel estimates heritability in the sense described by Fisher in
1918 as the amount of variation in liability to develop cancer that is
explained by genetic variation. However, this variation can change
during the course of follow-up because cancer onset varies, for
instance, by age. Thus, it is critical to include time to diagnosis
in the biometric modeling of twin cancer data.
The biometric models developed for the NorTwinCan study
allows for studying how genetic and environmental sources of
variation to risk of cancer diagnosis vary over time, typically by
age (Scheike et al., 2014, 2015). All results take censored observa-
tions into account and hence will be independent of time of follow-
up. Further, the survival analysis approach allows for competing
risks typically death before diagnosis, the ‘alive-illness-death’ sce-
nario. Cancer-site specific characteristics — for instance, the
cumulative incidence function by age—may be compared to that
of the background population. Within-pair dependence is quali-
fied by the measures of case-wise concordance and of relative
recurrence risk that varies with age for MZ and DZ pairs.
Hence, the approach to model the risk of cancer determinants
described by Harvald and Hauge (1963) is extended to include
variation by age. This allows the estimation of the time varying her-
itability of risk of cancer as, for example, in prostate cancer by age
(Hjelmborg et al., 2014). The choice of risk scale allows for directly
comparable familial risk; for example, the case-wise concordance
in pairs that reflects the risk of cancer before a certain age condi-
tional on cancer onset in the co-twin before that age is also appli-
cable to siblings. Furthermore, the classic biometric modeling
approach described earlier in terms of ADCE variance components
is applied to the risk of cancer occurrence, taking time to diagnosis,
censoring or death into account (Holst et al., 2016), and has been
applied in the NorTwinCan analyses (Mucci et al., 2016). The key
assumption in the bivariate time-to-event modeling of twin cancer
data is that pairs are censored at the same time, which is indeed
the case for the registry data. The theory, including examples, is
discussed in Scheike et al. (2014, 2015), and the accompanying
R-package ‘mets’ implementing the survival analysis methods is
available from the CRAN library (Holst et al., 2016).
The matched case co-twin design allows for studying the asso-
ciation of the risk of cancer with exposures effectively controlling
for unobserved confounding. For instance, data on MZ pairs dis-
cordant for smoking are analyzed to study the direct effects of
smoking on lung cancer (Hjelmborg et al., 2017). Further, as dem-
onstrated in the article, the design allows for analyzing whether
genetic effects moderate the influence of smoking and vice versa,
that is, whether gene-by-smoking effects are influential for risk of
lung cancer.
Main Findings from NorTwinCan I
Prior to the updated linkages, a number of studies were published
based on the data available inNorTwinCan I. Themain paper sum-
marizing the heritability and familial risk of cancer was published
in JAMA in 2016. The lifetime incidence of cancer in the cohort
was estimated to be 32%, based on 27,156 cancers diagnosed
among 23,980 twin individuals from same-sex pairs over a follow-
up period of 32 years on average. The familial risk, that is, the
cancer incidence in the co-twin given cancer in the first twin,
was estimated at 37% in DZ pairs and 46% in MZ pairs. The fam-
ilial risks were higher than the individual risks at all ages and were
also greater among the MZ than the DZ pairs at all ages. This pat-
tern indicates that a genetic liability to cancer is present throughout
life (Mucci et al., 2016). We show elsewhere (Skytthe et al., 2019)
that overall mortality and cancer incidence in the twins is compa-
rable to the background populations, thus permitting results from
the twin studies to be generalized to the population at large.
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The first Nordic analysis of cancer (Lichtenstein et al., 2000)
provided evidence for a genetic component for three of the most
common cancers (breast, prostate, colon). This list was expanded
based on NorTwinCan I analyses to also include melanoma and
nonmelanoma skin cancer, corpus uteri, ovary and kidney cancers
(Mucci et al., 2016). The NorTwinCan I analyses also considered
colon and rectum as separate sites. A more detailed analysis of
colorectal cancer (Graff et al., 2017) showed that the heritability
estimate for colorectal cancer as a single entity was 40% (95%
CI [33, 48]), the risks for colon cancer and rectal cancer specifically
being smaller. Indeed, the JAMA paper (Mucci et al., 2016) high-
lights that much of familial cancer risk is across sites, with a minor-
ity of pairs where both twins were diagnosed with cancer having
cancer at the same site. Even among MZ pairs, only 38% (522
out of 1383 cancer concordant pairs) had cancer at the same site,
compared to 26% (496 out of 1933 cancer concordant pairs) of DZ
pairs. Deeper analyses of these cross-site concordances were not
examined and are currently the focus of analyses being conducted
with the NorTwinCan II data. Heritability was estimated using
a model that included additive genetic (A) and non-shared (E)
environmental influences, common environment (C) was also
included in the model when there were five or more concordant
pairs. The point estimates for shared environment were greater
than zero for seven sites, but significant for lung cancer only
(24%, 307 95% CI [7, 40]) and breast (16%, 95% CI [10, 32])
(Mucci et al., 2016). Notably for overall cancer, the point estimate
for shared environment was zero despite more than adequate
power to detect such an effect — the heritability estimates for
all cancers being 33% (95% CI [30, 37]).
In addition to colorectal cancer (Graff et al., 2017), we have
examined familial risk and heritability of breast (Moller et al.,
2016) and prostate cancers (Hjelmborg et al., 2014) in more
detail. With a total of 3933 breast cancer cases in NorTwinCan
I, we observed greatly increased familial risk in both DZ pairs
(20%) and MZ pairs (28%) compared to the lifetime incidence
among individuals, estimated at 8%. This yielded a heritability
estimate of 31% overall, which was slightly lower when premeno-
pausal (27%) and postmenopausal (22%) cancers were consid-
ered separately. From age 50 onward, the MZ familial risk was
consistently higher than the DZ familial risk, and both were
higher than the individual risk, and the heritability estimate
did not vary by age (Moller et al., 2016). Notably, as individuals,
MZ and DZ female twins do not differ in incidence. In a further
analysis, twins from OSDZ pairs had the same breast cancer risk
as those from SS pairs (Ahrenfeldt et al., 2015), which did not
support the ‘twin testosterone transfer’ hypothesis of intrauterine
hormonal influences on cancer development. Ahrenfeldt et al.
(2015) showed similar results for other female (ovary, corpus
uteri, cervix and other female genitals) and male (prostate, testis)
cancers, further indicating lack of support for the testosterone
hypothesis.
For the prostate cancer analysis (Hjelmborg et al., 2014), we had
data on 4109 prostate cancer cases diagnosed in MZ, SSDZ and
males from OSDZ NorTwinCan pairs through 2009, which is a
slightly different analysis sample than reported in Mucci et al.
(2016). The differences in prostate cancer screening practices
between Denmark and the other Nordic countries result in a lower
incidence in Denmark; therefore, some analyses contrasted
Denmark with the other three countries. Thus, in addition to the
lifetime risk for prostate cancer being expectedly lower in Denmark,
the case-wise concordances were lower in Denmark. Despite that,
the heritability estimate was somewhat higher (59%) in Denmark
than for Finland, Norway and Sweden combined (52%). No
evidence for shared environmental effects overall was found, but
it may be present at younger ages (under 75 years). An analysis
by age suggested that heritability was quite constant with age.
In the NorTwinCan results described earlier, specific exposures
were not considered. One of the major risk factors for many can-
cers is smoking. Therefore, our first risk factor analysis considered
the effect of smoking on lung cancer incidence and familial risk.
For this purpose, we identified the twins with information on
smoking and followed them up for lung cancer incidence. In the
four Nordic cohorts, 115,407 twins (of whom 43,512 were MZ)
had smoking data, and we found 1508 incident lung cancers
(Hjelmborg, Korhonen et al., 2017). Expectedly, lung cancer risk
was strongly dependent on smoking status at baseline, with no
differences by zygosity and no differences by sex among never
smokers. The overall nine-fold higher risk among current smokers
was higher in men than in women. With only one concordant MZ
pair for lung cancer among more than 18,000 pairs of never smok-
ers, the heritability of lung cancer among never smokers could not
be estimated.
Most lung cancer concordant pairs were observed among pairs
in which both twins were current smokers at baseline. In such
pairs, we observed a higher concordance in MZ than DZ pairs.
Among current smoking pairs, the heritability of liability to lung
cancer was 0.41 (95% CI [0.26, 0.56]) under an AE model, and
0.29 under an ACE model. Finally, we examined lung cancer risk
in twin pairs in which one was a smoker at baseline and the other
had never smoked. There were 35 such discordant MZ pairs with
lung cancer incident in one twin; among them the lung cancer was
diagnosed in the current smoker for 31 pairs, in contrast to 4 pairs
in which the never smoker had lung cancer. The hazard ratio was
6.0 (95% CI [2.1, 17.3], p = .001). These results confirm the causal
role of smoking in lung cancer independent of genetic factors
(Hjelmborg, Korhonen et al., 2017). We are now continuing the
analyses to other cancers that are considered to be tobacco-related,
but for which the evidence for causality is less convincing, as
described here.
Current Ongoing Work — Cross-Cancer Associations
Analyses of the cross-cancer associations on the NorTwinCan II
data are ongoing. Model development was completed while await-
ing the updated data and preliminary analyses were conducted
using the NorTwinCan I data. Through a series of analyses, we
mapped the cross-cancer occurrences across 40 cancer sites. The
analyses of the within-pair associations took censoring and com-
peting risk of death into account. To explore the nature of the
cross-cancer associations we computed the following:
Cross-cancer concordances that represent the lifetime risk that a
pair will develop a particular combination of cancers.
Cross-case-wise concordance that estimates the risk to one twin for
a specific cancer given that the co-twin has a different specific
cancer.
Relative recurrence risks that provide information about how likely
the particular combination of cancer co-occurrences is in the
pair compared to nonrelated individuals.
Co-heritabilities of cancers estimated as twice the difference in life-
time concordance risk to the joint variation in risk. These esti-
mates reflect the importance of genetic influences for explaining
the relationships between sets of cancers.
Average within-pair differences between cancer occurrences, using
time to event analyses.
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The preliminary results were presented at the 16th Congress of
the International Society of Twin Studies (ISTS) in Madrid in 2017
(Harris et al., 2017). These indicated excess familial risk for a great
number of cancer co-occurrences, with estimates of coheritability
clearly stronger for specific cancer clusters. Furthermore, certain
cancers, such as prostate, breast and lung, tend to co-occur with
cancers at multiple sites.
The median difference in age at diagnosis was significantly
greater for some cancer co-occurrences and significantly less for
others. For example, the age difference at diagnosis for brain
and prostate cancer was 6.83 years among MZ pairs and 15.8 years
among DZ pairs. In contrast, age differences in diagnosis for the
co-occurrence of prostate and larynx cancer was 11.6 years among
MZ pairs and 3.09 years among DZ pairs. These findings suggest
that genetic effects influence the timing of disease development for
certain sets of cancer while unique environmental factors could in-
fluence the timing of diseases for other sets.
Our findings of co-heritability for many of the cross-cancer
associations may corroborate results from molecular studies.
Such studies provide an ever-growing number of genes identified
to be pleiotropic across cancers at different sites (Cheng et al.,
2014; Hoadley et al., 2014; Jiang et al., 2019; Lim et al., 2014;
Sampson et al., 2015; Setiawan et al., 2014; Sivakumaran et al.,
2011). A potential advantage of the twin design could derive from
comparisons between the twin-based and the molecular-based
results that can help elucidate the nature of the factors mediating
the cross-cancer occurrences. Co-heritable effects that are not
reflected inmolecular findings could signal genes or clusters of genes
that have not been identified. And cross-cancer associations that
show familiarity, but not significant co-heritability, could signal
common environmental influences that affect the risk of developing
cancer at specific sites.
We have extended the work on lung cancer and smoking
(Hjelmborg, Korhonen et al., 2017) to other tobacco-related can-
cers, as the evidence of the causal association of smoking with some
cancer types is less well established than for lung cancer. We used
the same data set as for the lung cancer analysis with never (n =
59,093), former (n = 21,168) or current (n = 47,314) smokers.
The focus was on incident cancer from the following sites —
bladder, esophagus, kidney, larynx, liver, oral cavity, pancreas
and pharynx — that showed an increased risk among smokers
in the NorTwinCan data base. Within-pair analyses of these indi-
vidual sites using smoking discordant pairs mostly found increased
estimates of risk in the smoking twin. But for several sites the
number of pairs discordant for both smoking at baseline and for
incident cancer was small and estimates were nominally nonsig-
nificant. When combined as ‘tobacco-related cancers’, the within-
pair association was strong and statistically significant even in MZ
pairs. This indicates that a common exposure such as smoking can
result in different cancers even when genetic and shared familial
environments are controlled for. A paper based on these results
is being finalized, and preliminary results have been presented
(Korhonen et al., 2017).
Cross-cancer analysis of brain with other cancers is another
area where our investigation of cancer concordance in twins is
revealing new findings. Despite the large sample size and median
of 32 years of follow-up in NorTwinCan I, concordance for cancers
of the brain and central nervous system (CNS) was rare. Only four
pairs (one MZ and three DZ pairs) were concordant for brain and
CNS cancers, corresponding to what would be expected by chance.
However, when we extended our analyses to cross-cancer occur-
rences of brain with other cancers, a different picture of genetic risk
begins to emerge. For example, the risk of brain cancer ismore than
doubled among MZ twins whose co-twin had skin cancer. We
also found an elevated concordance risk for brain cancer with
cancers of the prostate, breast, colon, kidney and leukemia.
These cross-cancer findings suggest that genetic effects are signifi-
cant across age at onset (Hjelmborg, Kaprio et al., 2017), andwill be
compared to findings emerging regarding genetic pleiotropy across
cancer sites.
Data Management, Ethics and Data Protection
In our experience with NorTwinCan, we find that moving and
updating large datasets across different national boundaries and
institutes is both complicated and cumbersome, requiring consid-
erable effort and resources to ensure data security. Solutions for
access can also be burdensome and restrict the analytical potential
of the collaborating scientists. An ideal solution would bypass data
transfer and exploit modern technologies that offer a single access
point to the datasets at participating locations. It also needs to
ensure data protection as is now formalized under the EU data
protection legislation (EU-GDPR, 2016).
One option under development is to establish data access through
the Nordic Tryggve collaboration project (https://neic.no/tryggve/).
Tryggve is funded through the Nordic e-Infrastructure Colla-
boration NeIC (branch of NordForsk), and the ELIXIR research
infrastructure nodes of the Nordic countries in NorTwinCan. The
goals are to develop a data management platform for sensitive
datasets that could satisfy the needs of research and researchers
using the NorTwinCan database. Tryggve is coordinated by the
Centre for Scientific Computing CSC, which is a Finnish govern-
mental body under the Ministry of Education offering high-
capacity data management and computation. Under Tryggve, a
researcher would access the datasets stored remotely in each of
the providing locations through a remote desktop and process
them in ePouta, a secure cloud for sensitive data provided by
CSC. The datasets themselves would be hosted by their respective
owners and secure, read-only access would be provided by Secure
Data Access Service (DAS). Of note is that the datasets would not
be copied from one location to another, but rather be accessible as
a streaming service, which retains the control of the datasets with
their respective owners.
Furthermore, all the researchers of the project would use the
same common virtual environment to access and process the data.
At the moment, a pilot demonstration of the system exists, and we
are working with Tryggve to implement the system. This model
will help extend data sharing and access beyond the scope of
any individual funded project and help build sustainable solutions
for collaboration. It could also serve as a model for other twin and
family dataset collaborations.
Discussion and Future Work
The NorTwinCan work summarized earlier extended the datasets
and analyses reported for the Nordic countries by Lichtenstein
et al. (2000) in several important ways. The follow-up time was
extended for the Danish, Finnish and Swedish cohorts, and the
Norwegian twins were added. Thus, the analysis of cancer in twins
covers a large fraction of all twins in the Nordic countries.
Furthermore, analyses of the NorTwinCan I data revealed that
the cancer incidence and overall mortality of the twin cohorts is
representative of the Nordic countries. The cumulative incidence
of any cancer is about one in three persons and provides a reliable
estimate of the population risk of cancer, while taking into
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consideration deaths from competing causes. Because cancer is
common, the patterns of cancer within families need to be viewed
within this population context. There are multiple sites where
cancer can occur, and different histologies and degrees of malig-
nancy. Investigating these patterns in both MZ and DZ pairs pro-
vides insights into the relative contributions of genes and
environment to variation in the liability to develop cancers overall
and to the most common cancers. Thus, we expanded findings
showing that the genetic component is significant across a greater
number of cancer sites than previously revealed, and for the most
common cancers (lung, breast, prostate and colorectal) we inves-
tigated particular features of their genetic epidemiology. The risk of
cancer diagnosis before 100 years of age and the lifetime risk
reported in Mucci et al. (2016) for 40 main sites fits those in the
corresponding background population, assuring external validity
of the twin model. This is not the case for corresponding lifetime
risks obtained from previously applied methodology (Lichtenstein
et al., 2000).
A key novel finding was that themajority of twin pairs concord-
ant for cancer were discordant for the cancer sites. This held true
even for MZ pairs, suggesting a general genetic proneness or resis-
tance, but that the actual tissue that develops cancer may be more
likely to be determined by nongenetic factors and stochastic effects.
This has led us to investigate the cross-site correlations of cancer
incidence, and to quantify to what degree reflect genetic factors
shared by different cancers (as defined by site), that is, genetic plei-
otropy or whether there are shared environmental determinants
(e.g., smoking exposure). These analyses are now ongoing using
the recent update, NorTwinCan II.
Finally, the data have been used to investigate whether
hormone-dependent and reproductive cancers such as breast
and prostate may be influenced by co-twin sex. The twin testoster-
one transfer hypothesis posits that female twins may be exposed in
utero to testosterone and be masculinized, which would affect their
risk of developing certain cancers. Using information on SS and OS
twin pairs, Ahrenfeldt et al. (2015) found no evidence to support the
hypothesis. This hypothesis continues to be of general interest in
potentially explaining some sex differences, and we can test more
specific hypotheses on selected cancers with the NorTwinCan II
update.
Estimates of the contribution of inter-individual genetic
differences to interindividual differences in risk of developing cancer
have been generated using family and twin data over the past dec-
ades. Much more recently, there has been an explosion in the
availability of measured genotypes using both array techniques
(to measure and impute common variants) and next generation
sequencing to measure rarer variants and whole genome sequences.
Genome-wide association studies of germline DNA from cancer
cases and controls have led to the identification of tens and hundreds
of loci or single nucleotide polymorphisms (SNPs) associated with
cancer risk and opened a window into the genetic variation under-
lying inherited risk to develop cancer. Furthermore, novel statistical
approaches have permitted the estimation of the contribution of all
measured and imputed genotypes to disease risk, a measure known
as SNP heritability. Comparisons of SNP-heritabilities and twin
heritabilities can give rise to hypotheses on the origins of familial
aggregations and sources of genetic variation.
The Nordic countries have immediate potential to take preci-
sion medicine forward (Njølstad et al., 2019), and the Nordic
Twin study on Cancer represents a major resource in the
Nordic portfolio of genetic, environmental and medical registers
and databases. Another set of resources are the biobanks in each
country. For example, the pathology archives from the past 30
years for virtually all cancer cases in Finland are available through
the network of national biobanks. This became possible through
new legislation, permitting more direct access by both academic
and commercial researchers to samples. Combining information
on family relationship, lifestyle and environmental exposures with
medical register data onmedications and comorbid conditions will
permit unparalleled investigations of the causes of cancer.
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